Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05709912 · ClinicalTrials.gov registry record · NA
Mobile CARE-App to Promote Coping for Caregivers of Patients Receiving Stem Cell Transplant
A NA study of Hematologic Malignancy and Bone Marrow Transplant Complications, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05709912: Active NA study of Hematologic Malignancy and Bone Marrow Transplant Complications, sponsored by Massachusetts General Hospital.
NCT05709912 is a NA study of Hematologic Malignancy and Bone Marrow Transplant Complications that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 120 participants, below the 226-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05709912, a NA study of Hematologic Malignancy and Bone Marrow Transplant Complications, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this research study is to determine whether a self-administered, psychosocial mobile application (CARE app) is effective at improving the quality of life and experience of caregivers of patients receiving hematopoietic stem cell transplantation (HCT).
Primary Outcome
Compare caregiver QOL as measured by the CARGOQOL between the two study groups. The CARGOQOL ranges from 0-100 with higher scores indicating better QOL
Conditions Studied
Interventions
- BEHAVIORAL Usual Care
- BEHAVIORAL CARE Application
Study Locations (1)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2026-12-01 |
| Phase | NA |
What the registry record for NCT05709912 still lists
NCT05709912 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 226-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (47% lower).
The record links to 2 conditions, with Hematologic Malignancy appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT05709912 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05709912 about?
NCT05709912 is a clinical study titled "Mobile CARE-App to Promote Coping for Caregivers of Patients Receiving Stem Cell Transplant". The goal of this research study is to determine whether a self-administered, psychosocial mobile application (CARE app) is effective at improving the quality of life and experience of caregivers of patients receiving hematopoietic stem cell transplantation (HCT).
What is the current status of trial NCT05709912?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2023-07-01. Estimated completion is 2026-12-01.
What conditions does trial NCT05709912 study?
This clinical trial studies the following conditions: Hematologic Malignancy, Bone Marrow Transplant Complications.
What interventions are being tested in trial NCT05709912?
The interventions under investigation include: Usual Care (BEHAVIORAL), CARE Application (BEHAVIORAL).
Who is sponsoring clinical trial NCT05709912?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05709912 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05709912's enrollment target sits among peer trials
120 10th of 48 higher than 39 of 48 other Hematologic Malignancy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Malignancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
-
Implementation of an Oral Chemotherapy Adherence Intervention
RECRUITING · NA
-
ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period
RECRUITING · NA
-
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
RECRUITING · NA
-
Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI